Niki BioSolutions, Inc. NIKI
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.58% | 28.00% | -12.42% | -12.42% | -37.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -67.28% | 8.56% | -582.68% | -582.68% | 8.00% |
| Total Operating Expenses | 55.91% | -14.85% | -67.19% | -67.19% | -70.49% |
| Operating Income | -55.91% | 14.85% | 67.19% | 67.19% | 70.49% |
| Income Before Tax | 59.69% | 15.36% | 83.11% | 83.11% | -168.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 59.69% | 15.36% | 83.11% | 83.11% | -168.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 102.01% | -89.34% | -49.33% | -49.33% | -175.06% |
| Net Income | 66.57% | 12.80% | 83.29% | 83.29% | -169.10% |
| EBIT | -55.91% | 14.85% | 67.19% | 67.19% | 70.49% |
| EBITDA | -63.57% | 7.25% | 71.70% | 71.70% | 70.27% |
| EPS Basic | 76.59% | 32.58% | 87.48% | 87.48% | -163.96% |
| Normalized Basic EPS | -30.40% | 31.33% | 66.90% | 66.90% | 89.35% |
| EPS Diluted | 76.59% | 31.03% | 87.48% | 87.48% | -163.96% |
| Normalized Diluted EPS | -30.40% | 31.33% | 66.90% | 66.90% | 89.35% |
| Average Basic Shares Outstanding | 42.78% | 29.35% | 33.46% | 33.46% | 8.03% |
| Average Diluted Shares Outstanding | 42.78% | 29.35% | 33.46% | 33.46% | 8.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |